Table 1.
Real-time PCR values for indicated target genes in mRNA purified from tendon tissue samples.
| Patient | Tendon tissue | State | Ct , mean ± SDa | |||
|---|---|---|---|---|---|---|
| GAPDH | IL-4Rα | IL-13Rα2 | IL-6 | |||
| 1 | FDL | Healthy | 23.3 ± 0.3 | 25.8 ± 0.6 | 26.1 ± 0.1 | 32.1 ± 0.1 |
| PTT | Diseased | 23.8 ± 0.2 | 24.7 ± 0.1 | 24.4 ± 0.4 | 32.2 ± 0.1 | |
| 2 | FDL | Healthy | 27.5 ± 0.7 | 32.4 ± 0.5 | 33.2 ± 0.5 | 37.0 ± 0.6 |
| PTT | Diseased | 24.7 ± 0.5 | 26.7 ± 0.1 | 25.6 ± 0.6 | 37.7 ± 0.9 | |
| 3 | FDL | Healthy | 25.0 ± 0.4 | 30.0 ± 0.8 | 31.3 ± 0.7 | 34.1 ± 0.9 |
| PTT | Diseased | 26.1 ± 0.5 | 29.6 ± 0.6 | 21.8 ± 0.8 | 35.0 ± 0.8 | |
| 4 | FHL | Healthy | 26.5 ± 0.3 | 27.1 ± 0.2 | ND | 38.8 ± 0.8 |
| AT | Diseased | 27.3 ± 0.1 | 30.0 ± 0.3 | ND | U | |
| 5 | FDL | Healthy | 27.9 ± 0.6 | 30.2 ± 0.5 | 31.1 ± 0.5 | 36.6 ± 0.7 |
| PTT | Diseased | 28.4 ± 0.7 | 30.0 ± 0.6 | 31.7 ± 0.7 | 35.8 ± 0.6 | |
| 6 | FDL | Healthy | 29.2 ± 0.9 | 32.4 ± 0.8 | 31.3 ± 0.7 | U |
| PTT | Diseased | 30.1 ± 0.9 | 32.2 ± 0.8 | 32.1 ± 0.9 | U | |
| 7 | FDL | Healthy | 29.1 ± 0.7 | ND | 28.8 ± 0.6 | 36.8 ± 0.9 |
| PTT | Diseased | 28.6 ± 0.6 | ND | 26.3 ± 0.5 | 37.0 ± 0.9 | |
| 8 | AT | Healthy | 25.5 ± 0.2 | 27.4 ± 0.4 | 27.5 ± 0.3 | 35.4 ± 0.8 |
| Diseased | 20.2 ± 0.1 | 22.7 ± 0.3 | 24.5 ± 0.3 | 34.4 ± 0.7 | ||
| 9 | AT | Healthy | 26.5 ± 0.4 | 29.3 ± 0.5 | U | 36.2 ± 0.7 |
| Diseased | 26.5 ± 0.3 | 25.9 ± 0.3 | 25.9 ± 0.6 | 31.0 ± 0.6 | ||
aEach cDNA sample was tested in triplicate.
AT = Achilles tendon; FDL = flexor digitorum longus; FHL = flexor hallucis longus; ND = no data (not tested); PTT = posterior tibial tendon; U = undetermined (no amplification up to PCR cycle 40).